Decorative
Decorative
DecorativeDecorative

Team

  • Our Mission

    To unlock the pharmaceutical potential of cannabinoids to treat diseases with significant unmet needs for patients around the world.

  • Our Values

    Collaboration
    We support a collaborative environment and know it takes people with different ideas, strengths, interests, and cultural backgrounds to make our company succeed.

    Passion
    Passion is at the heart of our company and drives every initiative. It is through our passion that we have fostered a unique relationship between business, medicine, and people; one that is personal and authentic.

    Integrity
    We uphold the highest standards of integrity in all that we do.

    Accountability
    We are accountable to each other and the patients we serve.

    Quality
    We take pride in advancing high-quality science that could translate into potentially transformative therapies for diseases with unmet needs.

  • Decorative
  • Management

    Punit Dhillon

    CEO

    Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.

    During his tenure at OncoSec, he oversaw and completed a partnership with Merck to launch Keynote 695, a Phase 2/3 global multi-center registration clinical study of late-stage metastatic melanoma, raised over $200 million and uplisted the company from the OTCQB to NASDAQ. Since moving on from this role, he has worked in various management capacities and helped to raise $500M for several companies, working together to reach essential milestones.

    His experience spans corporate finance, M&A, integration, successful in-licensing of key intellectual property, strategy implementation, international corporate transactions, and collaborations with leading universities and key opinion leaders.

    He also serves on the board of directors of other life science companies and acts as an advisor and consultant in several capacities to different life science organizations. He is the creator of Torpedo Publishing, a publishing imprint serving to connect, inspire, and educate future game changers looking to positively impact the world.

    Mr. Dhillon is the recipient of the Most Admired CEO award by the San Diego Business Journal in 2017, the BIOCOM Catalyst Award in 2018, the BASS Community Impact Award (SFU Beedie School of Business) in 2018, and has been recognized as a finalist for Ernst & Young’s Annual Entrepreneur of the Year in 2014.

  • Tu Diep,MSc

    Senior Vice President, Development

    Mr. Diep brings more than 15 years of scientific and clinical research experience to Skye Bioscience. Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc.

    Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc., (now Sophiris Bio Inc.), a company developing highly targeted, minimally invasive treatment for benign prostatic hyperplasia and prostate cancer. While at Protox, Mr. Diep held several positions with increasing responsibility where he gained extensive experience in preclinical research and development, clinical protocol development and design, clinical operations, and biologics manufacturing. Prior to leaving Protox, he was integrally involved in solidifying a $75 million regional partnership with a Japanese pharmaceutical company, as well as, securing a $35 million investment from the private equity firm, Warburg Pincus.

    In 2011, Mr. Diep joined OncoSec Medical Inc. as a founding employee. He led the development and initiation of the Company’s lead program, tavokinogene telsaplasmid (TAVO), an intratumoral gene therapy using DNA plasmid-encoding interleukin-12. As a key member of OncoSec’s executive management team, he spearheaded a key clinical collaboration with Merck to evaluate the combination of TAVO plus pembrolizumab, Merck’s leading anti-PD-1 antibody for the treatment of metastatic melanoma.

    Following OncoSec, Mr. Diep held positions as VP, Strategic Operations for a global cannabis company, Emerald Health Sciences, and in addition, held the role of Director, Business Process for a private next generation sequencing start-up, Element Biosciences. Mr. Diep holds a Master of Science in Physiology from the University of Toronto.

  • Richard Janney

    Principal Accounting Officer

    Richard has more than 30 years of business experience and served as a Vice President to CFO on multiple companies in a wide range of industries both public and private, domestic and international.

    Prior to Skye, Richard spent several years directing accounting, finance, tax, treasury, IT, HR and indirect purchasing of small to mid-size companies. During this time, he managed the worldwide accounting and finance functions for up to 20 legal entities as well as managed a worldwide staff of 65 accounting and finance personnel and directed the internal audit function for 5 mid-size public companies.

    In addition, he operated a private consulting firm where he worked for more than 15 companies ranging from small scale start-ups to mid-size companies, offering financial consulting services across an array of industries including software (i.e., SaaS and IaaS), semiconductor, manufacturing and medical devices. Mr. Janney has a B.S. in business administration degree from California Polytechnic University, SLO.

  • Tom Kim,Esq

    General Counsel & Director of IP

    Mr. Kim serves as the General Counsel and Director of IP at Emerald Bioscience. He is an experienced biotech executive and corporate attorney, and a registered patent attorney.

    Mr. Kim serves as the General Counsel and Director of IP at Skye Bioscience. He is an experienced biotech executive and corporate attorney, and a registered patent attorney. Prior to Skye, he served as SVP and Corporate Secretary for public biopharmaceutical company, Inovio Pharmaceuticals, where he built a global biotechnology patent portfolio, led the company through various M&A transactions, and closed several licenses and partnering deals with large pharmaceutical companies.

    Mr. Kim has counseled and managed several early-stage biotechnology companies and has experience counseling biotechnology companies for over 20 years. He has practiced law at both large law firms and at Fortune 100 companies including Monsanto and DuPont. Mr. Kim has a J.D. degree from Washington University in St. Louis, a M.S. in biochemistry degree from the University of Illinois, Urbana, and a B.S. in chemistry degree from the Georgia Institute of Technology.

  • Karam Takhar

    Vice President, Corporate Development & Investor Relations

    Karam Takhar serves as Vice President, Corporate Development & Investor Relations at Skye Bioscience Inc. Prior to joining Skye, Mr. Takhar was at Emerald Health Sciences.

    Karam Takhar serves as Vice President, Corporate Development & Investor Relations at Skye Bioscience Inc.

    Prior to joining Skye, Mr. Takhar served as an Executive Director at Emerald Health Sciences where he led the first operation in Canada to harvest hemp for cannabinoid extraction. Subsequently, he managed the Investor Relations program for Emerald’s portfolio of public and private cannabinoid science-driven companies, during which time the portfolio raised more than $100M in capital. Prior to Emerald, he has held various sales, marketing, and business development roles at leading life science companies including, Promega Corporation and Stemcell Technologies.

    Karam received his education from Simon Fraser University in British Columbia, Canada, where he earned his joint BSc (Hons) in Molecular Biology-Biochemistry and Business Administration. After which he went on to conducted graduate studies at the British Columbia Cancer Research Center in the Department of Experimental Therapeutics as part of the Pharmaceutical Sciences Program at the University of British Columbia.

Board of Directors

  • Punit Dhillon

    Chair

    Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.

    During his tenure at OncoSec, he oversaw and completed a partnership with Merck to launch Keynote 695, a Phase 2/3 global multi-center registration clinical study of late-stage metastatic melanoma, raised over $200 million and uplisted the company from the OTCQB to NASDAQ. Since moving on from this role, he has worked in various management capacities and helped to raise $500M for several companies, working together to reach essential milestones.

    His experience spans corporate finance, M&A, integration, successful in-licensing of key intellectual property, strategy implementation, international corporate transactions, and collaborations with leading universities and key opinion leaders.

    He also serves on the board of directors of other life science companies and acts as an advisor and consultant in several capacities to different life science organizations. He is the creator of Torpedo Publishing, a publishing imprint serving to connect, inspire, and educate future game changers looking to positively impact the world.

    Mr. Dhillon is the recipient of the Most Admired CEO award by the San Diego Business Journal in 2017, the BIOCOM Catalyst Award in 2018, the BASS Community Impact Award (SFU Beedie School of Business) in 2018, and has been recognized as a finalist for Ernst & Young’s Annual Entrepreneur of the Year in 2014.

  • Jim Heppell,LLB

    Director

    Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies.

    Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies. His first fund, the Advantage Life Sciences I Fund, won the Canadian Venture Capital Deal of the Year Award in 2006. Earlier in his career, he practiced corporate securities law with Fasken Martineau DuMoulin and later served as President and CEO of Catalyst Corporate Finance Lawyers. Mr. Heppell has also helped to build a number of life science companies, including Aspreva Pharmaceuticals (acquired by Galenica Ltd. SW: GALN), Immgenics (acquired by Amgen NASDAQ: AMGN), Inovio Pharmaceuticals (NASDAQ: INO), and Sophiris Bio Inc. (NASDAQ: SPHS). He earned a BSc in microbiology and a law degree from the University of British Columbia.

  • Margaret Dalesandro,PhD

    Director

    Dr. Dalesandro is the President of Brecon Pharma Consulting, a full-service biotech consultancy firm focused on identifying and obtaining critical information early in product development.

    With Brecon, Dr. Dalesandro has completed technical and commercial due diligence for biotechnology companies interested in in-licensing molecules for ocular indications.

    Dr. Dalesandro previously served as Business Director of Corning Integrative Pharmacology. Prior to that, as Vice President of Business Development and Portfolio Management at ImClone Systems Inc., she led the building of comprehensive development plans (from toxicology to market) for the use of Ramucirumab (a fully human VEGFR2 antibody) in age-related macular degeneration, and subsequently led negotiations to out-license a Ramicirumab Fab fragment to a major pharmaceutical company specializing in ophthalmic drug indications. At ImClone Systems she led the management of comprehensive development plans for Erbitux (Cetuximab) and made significant contributions to the $6.5 billion-dollar sale of the company to Eli Lilly in 2008.

    Previous to ImClone, Dr. Dalesandro served as an Executive Director at GlaxoSmithKline, managing cardiovascular, urology, and oncology drug product commercialization. Before GSK, Dr. Dalesandro was a senior consultant at Cambridge Pharma Consultancy. Earlier in her career, she was Director of Immunobiology and Diagnostic Research at Centocor and Assistant Director of Immunobiology. Dr. Dalesandro holds a Ph.D. and M.A. in Biochemistry from Bryn Mawr College and an A.B. in Biology and Chemistry from Rosemont College, where she graduated summa cum laude.

Scientific Advisory Board

  • Eduardo Muñoz,MD, PhD

    Scientific Advisor

    Dr. Muñoz is a Professor of Immunology in the Department of Cell Biology, Physiology, and Immunology of the University of Córdoba, Spain.

    Dr. Muñoz is also the Director of the inflammation and cancer research group at the Institute Maimonides for Biomedical Research of Córdoba. Dr. Muñoz has more than 30 years of experience in biomedical research and is the author of nearly 200 articles, patents, and book chapters with almost 5,000 citations. He is an expert in the mechanism of actions of cannabinoids and endocannabinoids as well as the development of cannabinoid-based new chemical entities. Dr. Muñoz belongs to the editorial board of several scientific journals and is a co-founder of two biotech companies, VivaCell Biotechnology (Spain) and Glactone Pharma AB (Sweden). He received a PhD in Medicine and Surgery at the University of Córdoba and was an associate researcher at Tufts University in Boston, and at the Institute Pasteur in Paris.

  • Giovanni Appendino,PhD

    Scientific Advisor

    Dr. Appendino is a Professor of Organic Chemistry, Department of Pharmaceutical Sciences at the University of Eastern Piedmont, Novara, Italy.

    Dr. Appendino has researched natural products for over 40 years, leading to the discovery and isolation of over 200 novel compounds, including novel phytocannabinoids and chemistry for cannabinoid-derived molecules. He is a Professor of Organic Chemistry, Department of Pharmaceutical Sciences at the University of Eastern Piedmont, Novara, Italy, where his research activities focus on isolation, chemical modification, and bioactive natural products synthesis. In recognition of his research, he was awarded the Rhône-Poulenc Rorer Award of the Phytochemical Society of Europe in 1991, the Quilico Medal of the Italian Chemical Society in 2009 the Bruker Prize of the Phytochemical Society of Europe in 2014. In 2018, he was elected to the Italian Academy of Sciences for his achievements in chemistry.

    Dr. Appendino has authored over 400 peer-reviewed articles, 15 book chapters, and 32 patents on natural products chemistry and bioactivity. He is Editor-in-Chief of the Journal Fitoterapia and editorial board member of the journals Acta Pharmaceutica Sinica B, Pharma Nutrition, Natural Products Research, Chinese Herbal Medicines, and the book series Progress in the Chemistry of Organic Natural Products.

Clinical Advisory Board

  • Jeffrey Goldberg,MD, PhD

    Ophthalmology Clinical Advisor

    Dr. Goldberg is the Professor and Chair of Ophthalmology and Director of the Spencer Center for Vision Research at the Byers Eye Institute at Stanford University.

    He received his undergraduate degree, magna cum laude, from Yale University, and his M.D./Ph.D. from Stanford University. Dr. Goldberg is a distinguished researcher investigating neuroprotection and regeneration of retinal ganglion cells and the optic nerve, a major unmet need in glaucoma and other optic neuropathies. He received the Cogan award from the Association for Research in Vision and Ophthalmology in 2012 and was elected in 2010 to the American Society of Clinical Investigation, an honorary society of physician scientists. Dr. Goldberg directs an NIH-funded research laboratory and has developed significant expertise with implementing clinical trials addressing optic nerve neuroprotection and regeneration. His laboratory is developing novel nanotherapeutic approaches for eye repair in addition to validating biomarkers associated with neuroprotection.

  • Louis Pasquale,MD, FARVO

    Ophthalmology Clinical Advisor

    Dr. Pasquale is the Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai in New York City.

    He is a Phi Beta Kappa graduate of Manhattan College and earned his M.D. degree from SUNY Stony Brook where he was selected for Alpha Omega Alpha, the national honor medical society. Dr. Pasquale is Site Chair of the Department of Ophthalmology at Mt. Sinai Hospital and Vice Chair of Translational Ophthalmology Research for the Mount Sinai Healthcare System. He currently serves as Glaucoma Trustee for the Association of Research in Vision and Ophthalmology (ARVO) and is a member of the National Institute of Health’s National Advisory Eye Council. He is a member of multiple editorial boards, including the Journal of Glaucoma, the American Journal of Ophthalmology, and Ophthalmology Glaucoma. Dr. Pasquale is an NIH Principal Investigator with continuous support since 2006.

  • Robert Ritch,MD

    Ophthalmology Clinical Advisor

    Dr. Ritch holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and is Clinical Professor of Ophthalmology at the Mt. Sinai Medical School and Surgeon Director Emeritus.

    Chief of Glaucoma Services at the New York Eye & Ear Infirmary of Mount Sinai, New York City. Dr. Ritch received his undergraduate degree from Harvard College and an M.D. degree from the Albert Einstein College of Medicine. He founded the Glaucoma Foundation and has contributed to multiple textbooks of ophthalmology, including more than 1500 published medical and scientific articles and abstracts. He has given over 50 named lectures and received 60 national and international awards. Dr. Ritch has served on the editorial boards of a number of professional journals including the Journal of Glaucoma, the Asia-Pacific Journal of Ophthalmology, and the Archives of Ophthalmology. He is a Diplomate of the American Board of Ophthalmology as well as a Fellow of the American Academy of Ophthalmology and the Royal College of Ophthalmology.

  • Miguel González-Andrades ,MD, PhD

    Ophthalmology Clinical Advisor

    Dr. Miguel González-Andrades is a clinician-scientist currently working as an ophthalmologist in the Ophthalmology Unit at Reina Sofia University Hospital.

    Dr. Miguel González-Andrades is a clinician-scientist currently working as an ophthalmologist in the Ophthalmology Unit at Reina Sofia University Hospital, and as an assistant professor and research scientist at Maimonides Biomedical Research Institute of Córdoba-University of Cordoba. Additionally, he serves since 2019 as an adjunct scientist at the Schepens Eye Research Institute and Mass Eye and Ear (SERI-MEEI), Harvard Medical School, after working there for five years leading different research projects on ocular biomedical engineering. Currently, he is the Chair of the Young Section of the European Society of Ophthalmology. During his clinical training and residency, Dr. González-Andrades focused his research on the construction of an artificial human cornea by applying tissue engineering techniques, obtaining his PhD Cum Laude in 2011 while serving as the coordinator for a multi-center phase I-II clinical trial evaluating artificial human corneas based on fibrin-agarose biomaterials.

    Dr. González-Andrades has been published in international journals such as Ocul Surf, Sci Rep, Biomaterials, and Nature Biomedical Engineering and has received numerous scientific awards, including the MIT Technology Review Spain - Innovators Under 35 Award and the Discovery Channel - Born to Be Discovery Award. He also received the Knights Templar Award from the Association for Research in Vision and Ophthalmology (ARVO), and the prestigious Claes Dohlman Fellowship Award that internationally recognizes outstanding fellows training in the specialty area of Cornea and External Diseases.